KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Debt Ratio (2016 - 2025)

Historic Debt Ratio for Halozyme Therapeutics (HALO) over the last 14 years, with Q4 2025 value amounting to 0.85.

  • Halozyme Therapeutics' Debt Ratio rose 1626.88% to 0.85 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.85, marking a year-over-year increase of 1626.88%. This contributed to the annual value of 0.85 for FY2025, which is 1626.88% up from last year.
  • Halozyme Therapeutics' Debt Ratio amounted to 0.85 in Q4 2025, which was up 1626.88% from 0.68 recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Debt Ratio registered a high of 0.88 during Q1 2023, and its lowest value of 0.06 during Q2 2022.
  • Moreover, its 5-year median value for Debt Ratio was 0.75 (2024), whereas its average is 0.61.
  • Per our database at Business Quant, Halozyme Therapeutics' Debt Ratio soared by 148642.17% in 2021 and then plummeted by 3603.07% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Debt Ratio (Quarter) stood at 0.79 in 2021, then grew by 3.03% to 0.82 in 2022, then grew by 5.76% to 0.86 in 2023, then fell by 15.64% to 0.73 in 2024, then increased by 16.27% to 0.85 in 2025.
  • Its Debt Ratio stands at 0.85 for Q4 2025, versus 0.68 for Q3 2025 and 0.73 for Q2 2025.